Go to
JCI Insight
Citations to this article
Linde A. Miles, … , John T. Poirier, Charles M. Rudin
Published June 26, 2017
Citation Information: J Clin Invest. 2017;127(8):2957-2967. https://doi.org/10.1172/JCI93472.
Citation Information: J Clin Invest. 2017;127(8):2957-2967. https://doi.org/10.1172/JCI93472.
Abstract
Seneca Valley virus (SVV) is an oncolytic picornavirus with selective tropism for neuroendocrine cancers. It has shown promise as a cancer therapeutic in preclinical studies and early-phase clinical trials. Here, we have identified anthrax toxin receptor 1 (ANTXR1) as the receptor for SVV using genome-wide loss-of-function screens. ANTXR1 is necessary for permissivity in vitro and in vivo. However, robust SVV replication requires an additional innate immune defect. We found that SVV interacts directly and specifically with ANTXR1, that this interaction is required for SVV binding to permissive cells, and that ANTXR1 expression is necessary and sufficient for infection in cell lines with decreased expression of antiviral IFN genes at baseline. Finally, we identified the region of the SVV capsid that is responsible for receptor recognition using cryoelectron microscopy of the SVV-ANTXR1-Fc complex. These studies identify ANTXR1, a class of receptor that is shared by a mammalian virus and a bacterial toxin, as the cellular receptor for SVV.
Authors
Linde A. Miles, Laura N. Burga, Eric E. Gardner, Mihnea Bostina, John T. Poirier, Charles M. Rudin
Total citations by year
Citation information
Citations to this article (44)
| Title and authors | Publication | Year |
|---|---|---|
|
Seneca Valley virus infection exploits DNA damage response to facilitate viral replication
Song J, Li Z, Yang J, Ma R, Wang D, Quan R, Wen X, Liu J |
Journal of Virology | 2025 |
|
ANTXR1 deficiency promotes fibroblast senescence. Implications for GAPO syndrome as a progeroid disorder.
Matthias Przyklenk, Shreya Karmacharya, Debora Bonasera, Stanislav Kmoch, Mats Paulsson, Raimund Wagener, Gianmaria Liccardi, Alvise Schiavinato |
Scientific Reports | 2024 |
|
Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer
Nia GE, Nikpayam E, Farrokhi M, Bolhassani A, Meuwissen R |
2024 | |
|
Identification of a linear B-cell epitope on the "puff" loop of the Senecavirus A VP2 protein involved in receptor binding.
Zhou H, Sun M, Su S, Meng L, Yang W, Yang L, Shi X, Li X, Wang H, Ma H, Cai X, Tang YD, An T, Meng F |
Frontiers in microbiology | 2024 |
|
Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities
Desai P, Takahashi N, Kumar R, Nichols S, Malin J, Hunt A, Schultz C, Cao Y, Tillo D, Nousome D, Chauhan L, Sciuto L, Jordan K, Rajapakse V, Tandon M, Lissa D, Zhang Y, Kumar S, Pongor L, Singh A, Schroder B, Sharma AK, Chang T, Vilimas R, Pinkiert D, Graham C, Butcher D, Warner A, Sebastian R, Mahon M, Baker K, Cheng J, Berger A, Lake R, Abel M, Krishnamurthy M, Chrisafis G, Fitzgerald P, Nirula M, Goyal S, Atkinson D, Bateman NW, Abulez T, Nair G, Apolo A, Guha U, Karim B, El Meskini R, Ohler ZW, Jolly MK, Schaffer A, Ruppin E, Kleiner D, Miettinen M, Brown GT, Hewitt S, Conrads T, Thomas A |
Cell reports. Medicine | 2024 |
|
A review of virus host factor discovery using CRISPR screening
See WR, Yousefi M, Ooi YS |
mBio | 2024 |
|
Directed Evolution of Seneca Valley Virus in Tumorsphere and Monolayer Cell Cultures of a Small-Cell Lung Cancer Model
Waqqar S, Lee K, Lawley B, Bilton T, Quiñones-Mateu ME, Bostina M, Burga LN |
Cancers | 2023 |
|
A Structure-Guided Genetic Modification Strategy: Developing Seneca Valley Virus Therapy against Nonsensitive Nonsmall Cell Lung Carcinoma
Zhao Z, Cao L, Sun Z, Liu W, Li X, Fang K, Shang X, Hu J, Chen H, Lou Z, Qian P |
Journal of virology | 2023 |
|
Targeting GBM with an Oncolytic Picornavirus SVV-001 alone and in combination with fractionated Radiation in a Novel Panel of Orthotopic PDX models.
Zhang H, Du Y, Qi L, Xiao S, Braun FK, Kogiso M, Huang Y, Huang F, Abdallah A, Suarez M, Karthick S, Ahmed NM, Salsman VS, Baxter PA, Su JM, Brat DJ, Hellenbeck PL, Teo WY, Patel AJ, Li XN |
Journal of Translational Medicine | 2023 |
|
Oncolytic viruses against cancer, promising or delusion?
Letafati A, Ardekani OS, Naderisemiromi M, Fazeli MM, Jemezghani NA, Yavarian J |
Medical Oncology | 2023 |
|
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
Wang X, Shen Y, Wan X, Hu X, Cai WQ, Wu Z, Xin Q, Liu X, Gui J, Xin HY, Xin HW |
Journal of Translational Medicine | 2023 |
|
Engineering Non-Human RNA Viruses for Cancer Therapy
Tur-Planells V, García-Sastre A, Cuadrado-Castano S, Nistal-Villan E |
Human vaccines | 2023 |
|
Seneca Valley virus 3Cpro antagonizes type I interferon response by targeting STAT1-STAT2-IRF9 and KPNA1 signals
Song J, Guo Y, Wang D, Quan R, Wang J, Liu J |
Journal of virology | 2023 |
|
TEM8 in Oncogenesis: Protein Biology, Pre-Clinical Agents, and Clinical Rationale
Kareff SA, Corbett V, Hallenbeck P, Chauhan A |
Cells | 2023 |
|
Seneca Valley virus 3C protease cleaves OPTN (optineurin) to Impair selective autophagy and type I interferon signaling
Song J, Guo Y, Wang D, Quan R, Wang J, Liu J |
Autophagy | 2023 |
|
Killing SCLC: insights into how to target a shapeshifting tumor
K Sutherland, A Ireland, T Oliver |
Genes & development | 2022 |
|
Senecavirus A- and Non-Infected Cells at Early Stage of Infection: Comparative Metabolomic Profiles
F Liu, B Ni, R Wei |
Frontiers in Cellular and Infection Microbiology | 2022 |
|
Disruption of anthrax toxin receptor 1 in pigs leads to a rare disease phenotype and protection from senecavirus A infection
P Chen, R Rowland, A Stoian, V Petrovan, M Sheahan, C Ganta, G Cino-Ozuna, D Kim, J Dunleavey, K Whitworth, M Samuel, L Spate, R Cecil, J Benne, X Yan, Y Fang, B Croix, K Lechtenberg, K Wells, R Prather |
Scientific Reports | 2022 |
|
Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions
D Luo, H Wang, Q Wang, W Liang, B Liu, D Xue, Y Yang, B Ma |
Frontiers in Oncology | 2022 |
|
Senecavirus A Entry Into Host Cells Is Dependent on the Cholesterol-Mediated Endocytic Pathway
M Jia, M Sun, Y Tang, Y Zhang, H Wang, X Cai, F Meng |
Frontiers in Veterinary Science | 2022 |
|
Improvements in pig agriculture through gene editing
Whitworth KM, Green JA, Redel BK, Geisert RD, Lee K, Telugu BP, Wells KD, Prather RS |
2022 | |
|
Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics.
Corbett V, Hallenbeck P, Rychahou P, Chauhan A |
Frontiers in Molecular Biosciences | 2022 |
|
Persistence and shedding of senecavirus A in naturally infected boars
Sturos MJ, Murray D, Johnson L, Preis G, Corzo CA, Rossow S, Vannucci FA |
Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc | 2022 |
|
The Evolution and Global Spatiotemporal Dynamics of Senecavirus A
Wu H, Li C, Ji Y, Mou C, Chen Z, Zhao J |
Microbiology spectrum | 2022 |
|
Experimental Senecavirus A Infection of Bovine Cell Lines and Colostrum-Deprived Calves.
Buckley A, Crawford L, Hoffman K, Falkenberg S |
Viruses | 2022 |
|
N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection
N Jayawardena, LA Miles, LN Burga, C Rudin, M Wolf, JT Poirier, M Bostina |
Viruses | 2021 |
|
Infectious recombinant Senecavirus A expressing novel reporter proteins
M Wang, C Mou, M Chen, Z Chen |
Applied Microbiology and Biotechnology | 2021 |
|
Tumor Endothelial Marker 8 Promotes Proliferation and Metastasis via the Wnt/β-Catenin Signaling Pathway in Lung Adenocarcinoma
C Ding, J Liu, J Zhang, Y Wan, L Hu, A Charwudzi, H Zhan, Y Meng, H Zheng, HP Wang, Y Wang, L Gao, X Hu, J Li, S Xiong |
Frontiers in Oncology | 2021 |
|
ANTXR1 as a potential prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma identified by a weighted gene correlation network analysis
T Si, X Ning, H Chen, Z Hu, L Dun, N Zheng, P Huang, L Yang, P Yi |
Journal of Gastrointestinal Oncology | 2021 |
|
Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development N Jayawardena, JT Poirier, LN Burga, M Bostina |
Oncolytic Virotherapy | 2020 |
|
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study
EL Schenk, SJ Mandrekar, GK Dy, MC Aubry, AD Tan, SR Dakhil, BA Sachs, JJ Nieva, E Bertino, CL Hann, SE Schild, TW Wadsworth, AA Adjei, JR Molina |
Journal of Thoracic Oncology | 2020 |
|
Seneca Valley Virus 3Cpro Cleaves PABPC1 to Promote Viral Replication
Q Xue, H Liu, Z Zhu, Z Xue, X Liu, H Zheng |
Pathogens | 2020 |
|
Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway
C Cai, W Dang, S Liu, L Huang, Y Li, G Li, S Yan, C Jiang, X Song, Y Hu, J Gu |
Cancer Science | 2020 |
|
Perspective of gene therapy with replication competent viruses
M Maemondo |
Translational Lung Cancer Research | 2020 |
|
Virus–Receptor Interactions: Structural Insights For Oncolytic Virus Development N Jayawardena, LN Burga, JT Poirier, M Bostina |
Oncolytic Virotherapy | 2019 |
|
Developing Picornaviruses for Cancer Therapy
McCarthy, Jayawardena, Burga, Bostina |
Cancers | 2019 |
|
A Novel Live Attenuated Vaccine Candidate Protects Against Heterologous Senecavirus A Challenge
B Sharma, MH Fernandes, M de Lima, LR Joshi, S Lawson, DG Diel |
Frontiers in immunology | 2019 |
|
Human tryptophanyl-tRNA synthetase is an IFN-γ-inducible entry factor for Enterovirus
Man Lung YEUNG, Lilong Jia, Cyril Yip, Jasper Fuk-Woo Chan, Jade Teng, Kwok-Hung Chan, Jian-Piao Cai, Chaoyu Zhang, Anna Jin-Xia Zhang, Wan Man Wong, Kin-Hang Kok, Susanna Lau, Patrick Woo, Janice Yee Chi Lo, Dong-Yan Jin, Shin-Ru Shih, K.Y. Yuen |
Journal of Clinical Investigation | 2018 |
|
Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth
DJ Evans, AM Wasinger, RN Brey, JM Dunleavey, BS Croix, JG Bann |
Frontiers in Oncology | 2018 |
|
Review of Seneca Valley Virus: A Call for Increased Surveillance and Research
X Zhang, Z Zhu, F Yang, W Cao, H Tian, K Zhang, H Zheng, X Liu |
Frontiers in microbiology | 2018 |
|
Structural basis for anthrax toxin receptor 1 recognition by Seneca Valley Virus
N Jayawardena, LN Burga, RA Easingwood, Y Takizawa, M Wolf, M Bostina |
Proceedings of the National Academy of Sciences | 2018 |
|
Emergence of a novel recombinant Seneca Valley virus in Central China, 2018
Z Wang, X Zhang, R Yan, P Yang, Y Wu, D Yang, C Bian, J Zhao |
Emerging Microbes & Infections | 2018 |
|
Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1
L Cao, R Zhang, T Liu, Z Sun, M Hu, Y Sun, L Cheng, Y Guo, S Fu, J Hu, X Li, C Yu, H Wang, H Chen, X Li, EE Fry, DI Stuart, P Qian, Z Lou, Z Rao |
Proceedings of the National Academy of Sciences | 2018 |
|
Cryo-Electron Microscopy Structure of Seneca Valley Virus Procapsid
M Strauss, N Jayawardena, E Sun, RA Easingwood, LN Burga, M Bostina, TS Dermody |
Journal of virology | 2017 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)